- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02282332
NIRS Ticagrelor Evaluation
The Impact of Ticagrelor on Coronary Atherosclerotic Lipid Pool and Inflammation Assessed by Near-Infrared Spectroscopy
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Single-Center, open-label study of the effect of ticagrelor on the reduction in the lipid pool in 30 patients with multi-vessel CAD 2 Treatment periods over 6 months, with 2 additional follow-up phone calls at 1 and 3 months.
Non-urgent PCI requiring stent placement and evaluation by NIRS/IVUS at baseline and 6 month follow up A second concomitant coronary lesion with diameter stenosis greater than 50% will also be imaged using NIRS/IVUS.
Patients will be discharged on a ticagrelor regiment of 90 mg twice a day for the 6 month study.
Blood samples will be drawn at baseline prior to ticagrelor being administered and again at follow up.
Inclusion Criteria:
- Female (post menopausal or surgically sterile) and/or male aged 18 years or older
- Multi-vessel coronary artery disease
- Statin therapy for minimum of 6 weeks prior to enrollment in the study with no plan for further adjustment
- Non-emergent PCI for ACS with stent placement requiring dual-antiplatelet therapy
- Ability to safely perform NIRS/IVUS for a concomitant non-culprit lesion with diameter stenosis ≥ 50% that was not treated with PCI
- Willing and able to sign informed consent and participate in follow-up
Exclusion Criteria:
- Thienopyridine or ticagrelor use in the last month
- Need for coronary artery bypass surgery or other surgeries during the follow-up period
- Documented medication non-compliance
- Chronic inflammatory disorder or treatment with anti-inflammatory or immunosuppressive drugs
- Prior or current malignancy within the last 5 years
- Concomitant severe illness or reduced life expectancy that will prevent follow-up cardiac catheterization
- Active infection
- Pregnant or lactating women
- End-stage renal disease
- History of intracranial hemorrhage
- Active pathological bleeding
- Known sever hepatic impairment
- Known hypersensitivity to ticagrelor
Study Procedures:
After consent is obtained non-urgent PCI requiring stent placement and evaluation by NIRS/IVUS at baseline is performed and once again at 6 month follow up. A second concomitant coronary lesion with diameter stenosis greater than 50% will also be imaged using NIRS/IVUS. Patients will be discharged on a ticagrelor regiment of 90 mg twice a day for the 6 month study.Blood samples will be drawn at baseline prior to ticagrelor being administered and again at follow up. There will be 1 month phone follow up, 3 month phone follow up and a 6 month clinical follow up that includes collecting blood, repeat catheterization, and repeat NIRS/IVUS procedure.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
• Female (post menopausal or surgically sterile) and/or male aged 18 years or older
- Multi-vessel coronary artery disease CAD
- Statin therapy for minimum of 6 weeks prior to enrollment in the study with no plan for further adjustment
- Non-emergent PCI for ACS with stent placement requiring dual-antiplatelet therapy
- Ability to safely perform NIRS/IVUS for a concomitant non-culprit lesion with diameter stenosis ≥50% that was not treated with PCI
- Willing and able to sign informed consent and participate in follow-up
Exclusion Criteria:
- Thienopyridine or ticagrelor use in the last month
- Need for coronary artery bypass surgery or other surgeries during the follow-up period
- Documented medication non-compliance
- Chronic inflammatory disorder or treatment with anti-inflammatory or immunosuppressive drugs
- Prior or current malignancy within the last 5 years
- Concomitant severe illness or reduced life expectancy that will prevent follow-up cardiac catheterization
- Active infection
- Pregnant or lactating women
- End-stage renal disease
- History of intracranial hemorrhage
- Active pathological bleeding
- Known severe hepatic impairment
- Known hypersensitivity to ticagrelor
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Patiens Discharged on Ticagrelor
Patients to be discharged on ticagrlore regiment of 90mg twice a day for 6 months.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change From Baseline Lipid Pool to Follow up as Assessed by NIRS/IVUS With Treatment of Ticagrelor
Zeitfenster: 6 months
|
Treatment with ticagrelor following PCI will lead to significant 20% reduction in the LCBI as assessed at follow up by NIRS/IVUS when compared with baseline imaging data of the reference vessel, suggesting a reduction in inflammation and stabilization of the lipid core in atherosclerotic lesions not treated during the index procedure.
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change From Baseline Inflammatory Markers to Follow up With Treatment of Ticagrelor
Zeitfenster: 6 months
|
We expect to see a significant reduction of inflammatory markers of Hs-CRP, MCP-1, IL-1, IL-6, IL-18, and TNF- α as well as an increase in IL-10, a cytokine associated with a reduction in inflammation, following therapy with ticagrelor when compared with baseline values.
This is expected as inflammatory markers should be lower in stable coronary artery disease compared with patients presenting with ACS.
While there is no control group in the proposed study, it will be important to assess whether changes in established biomarkers associated with inflammation correlate with changes in LCBI.
While ticagrelor was not shown to reduce inflammatory biomarkers to a greater degree than clopidogrel, it will be important to assess whether the reduction in LCBI is independent of or associated with reductions in inflammatory markers or platelet reactivity.
|
6 months
|
Mitarbeiter und Ermittler
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Myokardischämie
- Herzkrankheiten
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Arteriosklerose
- Arterielle Verschlusskrankheiten
- Koronare Krankheit
- Koronare Herzkrankheit
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Thrombozytenaggregationshemmer
- Purinerge P2Y-Rezeptorantagonisten
- Purinerge P2-Rezeptorantagonisten
- Purinerge Antagonisten
- Purinerge Wirkstoffe
- Ticagrelor
Andere Studien-ID-Nummern
- AZ_ISSBRIL0304
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Ticagrelor
-
Federico II UniversityAdvicePharma GroupAbgeschlossenHerzinfarkt | Koronare Herzkrankheit | Akutes Koronar-Syndrom | STEMI | NSTEMIItalien
-
Collegium Medicum w BydgoszczyAbgeschlossen
-
University of FloridaAbgeschlossen
-
AstraZenecaParexelAbgeschlossen
-
AstraZenecaAbgeschlossenHerzinfarkt | Streicheln | Atherothrombose | Herz-Kreislauf-TodSchweden, Vereinigte Staaten, Australien, Brasilien, Bulgarien, Tschechische Republik, Frankreich, Italien, Korea, Republik von, Peru, Polen, Russische Föderation, Südafrika, Spanien, Truthahn, Vereinigtes Königreich, De... und mehr
-
Bio-innova Co., LtdNoch keine Rekrutierung
-
Centro Hospitalario La ConcepcionRekrutierung
-
Azienda Ospedaliero Universitaria di SassariAstraZenecaAbgeschlossenMyokardinfarkt mit ST-Hebung | NSTEMI – Nicht-ST-Streckenerhöhung MIItalien
-
Sheba Medical CenterAbgeschlossenMyokardinfarkt mit ST-Hebung | Akute KoronarsyndromeIsrael
-
David AntoniucciAstraZeneca; A.R. CARD Onlus FoundationAbgeschlossenAkutes Koronar-Syndrom | Nebenwirkung auf ThrombozytenaggregationshemmerItalien, Griechenland